Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Trading Up 0.9 %

NYSE:LLY traded up $2.87 on Monday, reaching $310.95. 7,236 shares of the stock traded hands, compared to its average volume of 2,889,338. The firm has a market capitalization of $295.46 billion, a price-to-earnings ratio of 49.14, a price-to-earnings-growth ratio of 2.10 and a beta of 0.35. The company's 50 day moving average is $315.45 and its 200-day moving average is $291.91. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. Eli Lilly and has a 1-year low of $220.20 and a 1-year high of $335.33.

Eli Lilly and (NYSE:LLY - Get Rating) last released its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.86 by ($0.61). The business had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The company's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.87 earnings per share. Equities research analysts anticipate that Eli Lilly and will post 7.96 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be paid a $0.98 dividend. The ex-dividend date of this dividend is Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. Eli Lilly and's dividend payout ratio is currently 62.52%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LLY shares. Morgan Stanley lifted their target price on Eli Lilly and from $369.00 to $395.00 and gave the company an "overweight" rating in a report on Friday, July 8th. JPMorgan Chase & Co. upped their price target on Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. StockNews.com downgraded Eli Lilly and from a "strong-buy" rating to a "buy" rating in a report on Friday, August 5th. Mizuho increased their target price on Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Finally, SVB Leerink began coverage on Eli Lilly and in a report on Monday, May 23rd. They issued an "outperform" rating and a $341.00 target price for the company. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and has a consensus rating of "Moderate Buy" and a consensus target price of $317.00.

Insider Transactions at Eli Lilly and

In other news, SVP Alonzo Weems sold 656 shares of the firm's stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $304.50, for a total value of $199,752.00. Following the transaction, the senior vice president now owns 8,136 shares of the company's stock, valued at $2,477,412. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of the business's stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the transaction, the senior vice president now directly owns 8,136 shares of the company's stock, valued at approximately $2,477,412. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,115,291 shares of company stock valued at $355,901,728. Insiders own 0.12% of the company's stock.